Phase 3 study of IPX066 for Parkinson's disease
April 20, 2009 - Impax Pharmaceuticals announced it has commenced a Phase 3 trial of IPX066 to treat Parkinson's disease (PD) based on encouraging interim data collected from its Phase 2 study in PD patients. This study, known as APEX-PD, will be the first of two Phase 3 studies and will include Parkinson's disease patients with mild symptoms of PD. Impax is planning to commence a second Phase 3 trial of IPX066 in patients with advanced PD patients later in 2009 or early 2010.
IPX066 is an investigational extended-release carbidopa-levodopa product designed to produce a fast and sustained concentration of levodopa, potentially improving PD clinical symptom management. Fonte:
Empr.
__________________________________________________
Boehringer makes progress on Parkinson's treatment
Tuesday, February 23, 2010 - Boehringer Ingelheim Pharmaceuticals Inc. has made advances in its work on Parkinson's disease and sexual dysfunction amongst women.
The Ridgefield-based company Monday received approval from the Food and Drug Administration for an extended-release tablet for Mirapex ER, a medication used to treat early symptoms of Parkinson's. (segue...) Fonte:
News Times.
Trata-se de dois medicamentos, carbidopa + levodopa (IPX066) e Pramipexole (Mirapex / Sifrol), ambos com liberação extendida/prolongada, em fase próxima de lançamento.
It’s a rare thing to find someone as generous and kind as you. Thanks for helping all by posting this valuable information in this great article.
ResponderExcluir